期刊文献+

小剂量两性霉素B脂质体在老年隐球菌性脑膜炎诱导期治疗中的疗效及肾毒性观察

Curative effect and renal toxicity observation on small dose liposomal amphotericin B in treatment of elderly cryptococcal meningitis in induction period
下载PDF
导出
摘要 目的 观察小剂量两性霉素B脂质体(1iposomal amphotericin,L-AmB)在老年隐球菌性脑膜炎诱导期治疗中的疗效及肾毒性。方法 回顾性分析2008年1月-2014年12月收治的使用小剂量L-AmB治疗的老年隐球菌性脑膜炎患者14例为观察组,同期住院的使用常规剂量L-AmB治疗的患者17例作为对照组,分析比较两组的差异。结果 两组患者治疗后总有效率、无效率、死亡率比较差异均无统计学意义,但是对照组治疗后的肾功能损害及低钾血症比例仍明显高于观察组,两组比较差异有统计学意义(P〈0.05);治疗后,观察组肾小球滤过率较治疗前稍下降,差异无统计学意义,而对照组肾小球滤过率较治疗前明显下降,差异有统计学意义(P〈0.05)。结论 小剂量两性霉素B脂质体在老年隐球菌性脑膜炎诱导期治疗中疗效肯定,肾毒性减轻。 Objective To observe the curative effect and renal toxicity of small dose liposomal amphotericin B(L-AmB)in treatment of elderly cryptococcal meningitis in induction period.Methods 14 cases of elderly cryptococcal meningitis treated by small dose L-AmB between January 2008 and December 2014 were reviewed and selected as the observation group.Another 17 elderly cryptococcal meningitis patients treated by regular dose L-AmB in same period of time were chosen as the control group.Differences between the two groups were compared.Results There was no statistically significant difference in total effective rate,non-effective rate and mortality rate of patients in two groups after treatment.However,the renal function damage and proportion of hypokalemia in the control group were evidently higher than those in the observation group with statistical significance(P〈0.05).After treatment,the glomerular filtration rate in the observation group reduced slightly than that before treatment,without statistical significance;while the glomerular filtration rate in the control group reduced statistically significantly than that before treatment,with statistecal significance(P〈0.05).Conclusion The curative effect of small dose liposomal amphotericin B is positive in treatment of elderly crvotococcal meningitis in induction period,with reduced renal toxicity.
出处 《中国现代医生》 2015年第36期107-110,共4页 China Modern Doctor
基金 浙江省医药卫生科技计划项目(2014KYA084)
关键词 隐球菌性脑膜炎 两性霉素B脂质体 诱导期治疗 肾毒性 Cryptococcal meningitis Liposomal amphotericin B Induction period treatment Renal toxicity
  • 相关文献

参考文献20

  • 1Perfect JR,Dismukes WE,Dromer F,et al. Clinical prac- tice guidelines for the management of eryptoeoeeal dis- ease:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3) : 291-322.
  • 2陈瑞玲,赵志刚.两性霉素B及其新型制剂的合理应用[J].中国药学杂志,2005,40(20):1595-1596. 被引量:12
  • 3Gullo FP,Rossi SA,Sardi JC,et al. Cryptococcosis:Epi- demiology,fungal resistance,and new alternatives for treat- ment[J]. Eur J Clin Microbiol Infect Dis,2013,32 (11): 1377-1391.
  • 4Siedner MJ, Campbell J], Kanters S, et al. Combination therapy tr human immunodeficiency virus-associated eryptococcal meningitis:Whom,when,and where?[J]. Open Forum Infect Dis,2015,2(2) :68-75.
  • 5翁心华,朱利平.重视隐球菌脑膜炎的治疗[J].中华传染病杂志,2007,25(4):193-194. 被引量:18
  • 6Chen J,Varma A,Diaz MR,et al. Cryptococcus neoformans strains and infection in apparently immunocompetent pa- tients, China[J]. Emerg Infect Dis, 2008,14(5) : 755-762.
  • 7Chou PH, Ouyang WC, Lan TH, et al. Secondary mania due to AIDS and cryptococcal meningitis in a 78-year- old patient[J]. Psychogeriatrics,2015,27: 12127.
  • 8Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: Diagnosis and management update[J]. Curt Trop Med Rep,2015,2(2):90-99.
  • 9Wade RL, Chaudhari P, Natoli JL,et al. Nephrotoxicity and other adverse events among inpatients receiving lipo somal amphotericin B or amphotericin B lipid complex[J]. Diagn Microbiol Infect Dis, 2013,76 ( 3 ) : 361- 367.
  • 10Brajtburg J,Elberg S,Kobayashi GS,et al. Effects of aseor- bic acid on the anti fungal action of amphotericin B[J]. J Antimicrob Chemother, 1989,24(3) : 333-337.

二级参考文献23

  • 1陈新谦 金有豫 汤光.新编药物学15版[M].北京:人民卫生出版社,2003.57-76.
  • 2国家药典委员会.临床用药须知2000年版:二部[M].北京:化学工业出版社,2001.735-737.
  • 3Hann IM, prentice HG . Lipid-based amphotericin B: a review of the last 10 years of used[J]. Int J Antimicrob Agents ,2001,17(3): 161.
  • 4Arikan S. Lipid-based antifungal agents, a concise overview[ J ]. Cell Mol Biol Lett ,2002,7(3) :919.
  • 5Rust DM, Jameson G. The novel lipid delivery ssystem of amphotericin B:drug profile and relevance to clinical practice[ J ]. Oncol Nurs Forum, 1998,25(1) :35.
  • 6Cannon JP, Fiscella R, Pattharachayakul S, et al. Comparative toxicity and concentration of intravitreal amphotericin B formulation in a rabbit model[J]. Inve Ophthal and Vis Sci ,2003,44:2112
  • 7de Marie S, Janknegt R, Bakker-Woundenberg IA. Clinical use of liposomal and lipid complexed AmB[J] .J Antimicrob-Chemotherapy,1994,33(5) :907.
  • 8Amato VS, Rabello A, Rotondo-Silva A, et al. Succesful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients[ J ] . Acta Trop , 2004,92 (2): 127.
  • 9David WD, Peter W. Dose range evaluation of liposomal nystation and comparisions with amphotericin b and amphtropenic mice infected with an isolate of aspergillus fumigatus with reduced susceptibility to AmB [ J ] . Antimicrobial Agents and Chemotherapy,1999,11 (43):2592.
  • 10Belloccgio S, Gaziano R, Bozza, et al. Liposomal amphotericin B activates antifungal resiistance with reduced toxicity by diverting tolike receptor signalling from TLR-2 to TLR-4[J] .J Antimicrob Chemother,2005,55(2) :214.

共引文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部